Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Tommy G. Thompson, a director at United Therapeutics Corp (NASDAQ:UTHR), a $13.8 billion market cap company with impressive 89% gross margins and a perfect Piotroski Score of 9 according to InvestingPro, has sold shares worth approximately $795,837. The transaction, which occurred on February 28, involved the sale of 2,500 shares of common stock at an average price of $318.34 per share, amid a recent 10.7% weekly decline in the stock price. Following this sale, Thompson now holds 8,480 shares directly.
Additionally, Thompson exercised stock options to acquire 2,500 shares at $175.43 each, amounting to a total of $438,575. This transaction also took place on February 28. Post these transactions, Thompson’s direct ownership stands at 5,000 shares, with indirect holdings of 8,200 shares by a trust and 5,800 shares through a family LLC. The company, currently trading at an attractive P/E ratio of 11.7, shows strong financial health with a "GREAT" rating on InvestingPro, which offers 12 additional key insights about UTHR’s investment potential.
In other recent news, United Therapeutics Corporation reported its fourth-quarter 2024 earnings, which fell short of analyst expectations. The company posted an earnings per share (EPS) of $6.19, below the anticipated $6.68, and revenue reached $735.9 million, slightly under the forecasted $739.92 million. Despite this, United Therapeutics achieved record annual revenue growth for the third consecutive year, with key products like Tyvaso and Orenitram showing strong revenue increases of 19% and 28%, respectively.
Goldman Sachs analyst Chris Shibutani adjusted the price target for United Therapeutics to $293 from $302, maintaining a Neutral rating. This revision was influenced by a modest reduction in Tyvaso forecasts and increased research and development spending. The company’s Tyvaso product experienced a roughly 4% sequential decline, attributed to contracting efforts and potential competition from LQDA’s Yutrepia expected in May 2025.
United Therapeutics continues to advance its pipeline with significant clinical trial progress, including the anticipated outcomes of the IPF trials, TETON-2 and TETON-1, seen as critical for reinforcing confidence in sustained growth. The company remains optimistic about its growth prospects, projecting continued double-digit revenue growth into the mid-decade, with potential new products like Ralinepag and Tyvaso for idiopathic pulmonary fibrosis contributing significantly.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.